key: cord-1048909-1b6eu9ok authors: Walsh, Martin A.; Grimes, Jonathan M.; Stuart, David I. title: Diamond Light Source: contributions to SARS-CoV-2 biology and therapeutics date: 2020-11-19 journal: Biochem Biophys Res Commun DOI: 10.1016/j.bbrc.2020.11.041 sha: 2c07c407fb6139a21066dd3b217fe7e9da549fab doc_id: 1048909 cord_uid: 1b6eu9ok The impact of COVID-19 on public health and the global economy has led to an unprecedented research response, with a major emphasis on the development of safe vaccines and drugs. However, effective, safe treatments typically take over a decade to develop and there are still no clinically approved therapies to treat highly pathogenic coronaviruses. Repurposing of known drugs can speed up development and this strategy, along with the use of biologicals (notably monoclonal antibody therapy) and vaccine development programmes remain the principal routes to dealing with the immediate impact of COVID-19. Nevertheless, the development of broadly-effective highly potent antivirals should be a major longer term goal. Structural biology has been applied with enormous effect, with key proteins structurally characterised only weeks after the SARS-CoV-2 sequence was released. Open-access to advanced infrastructure for structural biology techniques at synchrotrons and high-end cryo-EM and NMR centres has brought these technologies centre-stage in drug discovery. We summarise the role of Diamond Light Source in responses to the pandemic and note the impact of the immediate release of results in fuelling an open-science approach to early-stage drug discovery. The rapid spread of a novel coronavirus led to the second pandemic of the 21 st century being declared by the World Health Organisation on the 11 th March 2020 [1] . This virus, SARS-Cov-2 [2] , has been directly responsible for over 1.2 million deaths as of 1 st November 2020 [3] . Furthermore the world economy has been severely affected [4, 5] . Although two previous coronavirus outbreaks causing severe disease have occurred since 2002, namely severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), no antivirals or vaccines have been approved to combat these and probable future zoonotic coronavirus outbreaks. As observed in April by Stephen Burley this represents market failure [6] . Nevertheless the COVID-19 pandemic has generated an unprecedented response from the scientific community -currently more than 95,000 publications on SARS-CoV-2 research (https://www.who.int/emergencies/diseases/novel-coronavirus-2019/globalresearch-on-novel-coronavirus-2019-ncov). With the knowledge accumulated since the first SARS outbreak in 2002 this is transforming our understanding of coronaviruses, from genome organisation [7, 8] to cell entry, replication, release and pathogenesis [9] . The speed of response from the structural biology community was remarkable. The deposition of the SARS-Cov-2 genome sequence [10] [11] [12] [13] on the 11 th January 2020 made it routinely in the range of 3 -4 Å, and continued developments mean that genuine atomic resolution is now achievable [25, 26] . Here, we highlight the central role of technical advances and large scale infrastructure in enabling the remarkable response to the pandemic, focussing primarily on the role played by Diamond Light Source. 2. SARS-CoV-2 main protease (M pro )-a prime target for drug discovery The main viral protease (M pro ) of SARS-CoV-2 plays an essential role in viral replication and has been extensively studied to identify inhibitors of SARS-CoV-1, MERS and now SARS-CoV-2 replication [27] [28] [29] [30] . Since it is present in all coronavirus genera it has the potential to act as a target for the development of broad-spectrum antivirals [31] , so an extremely potent drug (sub nM) may well also protect against the next coronavirus incursion. Being a medium sized (33.8 kDa), stable enzyme that expresses well and crystallises readily, M pro is well suited as a target for structure-based drug discovery [34, 35] . M pro is encoded by nonstructural protein 5 (nsp5) and is responsible for the proteolytic cleavage at 11 sites of the polyproteins pp1a and pp1ab ( Fig. 1 ) [36] . Capitalising on their extensive knowledge of the structural biology of SARS nsps and in particular M pro , Zihe Rao and Haitao Yang mobilised their groups in Shanghai to target the structure of M pro and other key SARS-CoV-2 replicase proteins. Remarkably they were able to determine the structure of M pro in complex with a covalent inhibitor N3 [37] by mid-particular, whether an X-ray fragment based drug discovery campaign could be initiated using the XChem platform. In the first instance the aim was to complement the efforts in Shanghai at fast tracking repurposing of drugs while bringing us on board to lay the groundwork for developing, ab initio, antivirals targeting SARS-CoV-2 M pro . Unfortunately, the lock-down in China prevented the rapid exchange of materials, and we were forced to re-clone and overexpress using their protocols [34] . By mid-February we had obtained well diffracting, robust, ligand-free crystals of M pro suitable for soaking in low molecular weight fragments to carry out a high-throughput fragment screening XChem campaign [39] , diffracting to atomic resolution (1.25 Å), with M pro arrayed within the crystal lattice with the active site accessible to compounds (Fig 2a) . A large-scale screen of electrophile (a collaboration with Nir London, Weizmann Institute, Israel) and non-covalent fragments through a combined mass-spectrometry and X-ray approach resulted in 71 hits that comprehensively sampled the active site of M pro , and 3 hits at the dimer interface [14] . This wealth of information enabled us to rapidly elaborate these initial weakly binding hits into more potent inhibitors through merging covalent and non-covalent fragments (Fig. 2b) . To maximise the impact of the results, we released the data immediately, through a dedicated portal (https://www.diamond.ac.uk/covid-19.html) and deposition of the data with the PDB. [41] . This work represents a novel response to the drug discovery problem, however the next stages will be crucial, there is an urgent need to increase potency by two orders of magnitude, meanwhile and routes for development need to be established. This approach will not provide a 'quick fix' but might provide antivirals effective against this and future coronavirus zoonoses. Repurposing approved drugs certainly can provide a fast-track to a therapy. Screening of approved drugs and those with pre-clinical safety data has been facilitated by the ReFrame library [42, 43] of 12,000 compounds approved for clinical investigation in humans, including all currently approved drugs. We have collaborated with Exscientia (https://www.exscientia.ai/) to test this library against several targets. A number of approved drugs have been shown to inhibit SARS-CoV-2 M pro at low micromolar concentrations and show antiviral activity in cellular assays [37, 44, 45] . To date the most effective repurposed drug against COVID-19 is the anti-inflammatory dexamethasone [46] . The ribonucleotide remdesivir has been proposed as a potential anti-viral treatment for act as templates for viral messenger RNAs to express structural proteins. Which are the building blocks for new virus particles. These steps remain poorly understood but occur in the membrane-associated replication-transcription complex (RTC), formed by nsps 1-16. Nsp12 is the RNA-dependent RNA polymerase component and requires nsp7 and nsp8 for processivity and modulation of activity. Nsp12 adopts the canonical right-handed RNA polymerase fold, linked to an N-terminal domain implicated in nucleotidyltransferase activity [48] . One nsp7 and two nsp8 molecules form a complex with each nsp12. A number of publications have revealed the overall architecture of the SARS-CoV-2 nsp12/7/8 complex, and the structural changes that occur on RNA binding [15, [49] [50] [51] [52] [53] . Early in February 2020 we ordered the synthetic genes for nsp12, nsp7 and 8, and by the 9 th of March were able to visualise protein bands on a gel. Nsp7 and nsp8 were expressed in bacteria and nsp12 in insect cells, with the complex formed by mixing nsp7, nsp8 and nsp12 in a molar ratio of 2:2:1. Initially cryoEM analyses were hampered by the tendency of the complex to fall apart during grid preparation. We overcame this problem by addition of an overhanging RNA duplex of sufficient length (34/40mer) -recapitulating the work by the group of Patrick Cramer [15] (Fig. 3) . Work continues to understand if and how the polymerase forms higher order complexes with other nsps that are thought to be involved in processing the viral RNA in both replication and cap synthesis for mRNA synthesis. These include nsp10 which is a co-factor for nsp14 (N7-methyltransferase/3′-5′ exonuclease activity) and for nsp16 (2′-O-methyltransferase) as well as nsp13 (helicase) and nsp15 (Endoribonuclease/5′ triphosphatase). Alongside the structural work we have developed an in vitro RNA synthesis assay which we are using to screen for polymerase inhibitors [54] . J o u r n a l P r e -p r o o f The coronavirus spike is trimeric with each subunit comprising some 1200 residues. It attaches to the host receptor and is cleaved into two chains (S1 and S2) to form a metastable structure which undergoes massive rearrangements to fuse the host and virus membranes, releasing the viral genome into the host cell. It is challenging to express a soluble form of the protein that remains trimeric and does not convert into the post-fusion state. Prior studies of homologues allowed these problems to be rapidly overcome and the McLellan laboratory reported a structure for the prefusion form in March [19] . Our work on this system began in February when it became clear that there was immediate value in understanding how human antibodies interact with the spike, to inform the selection of potential therapeutic antibodies. In addition, we realised that high quality spike antigen would be a invaluable reagent for the high throughput ELISA platform we were developing to test immune responses [55] . The centre of gravity for this work was the Division of [56, 58] . Work has meanwhile been carried out by others across the world, and a reasonably consistent picture is emerging from studies of monoclonal antibodies from convalescent and recovered patients [59] [60] [61] . The majority of antibodies that recognise spike do not neutralise. Most neutralising antibodies bind to the small receptor binding domain, which lies at the top of the spike, usually folded down, but capable of reaching up to engage the cell receptor, ACE2. These neutralising antibodies appear to work by preventing attachment to the ACE2 receptor. However the results of our collaborative research on antibodies CR3022 and EY6A demonstrated another route to neutralisation, through destabilisation of the prefusion spike [56, 58] (Fig.4) . Such observations are of interest since numerous clinical trials are planned or underway to investigate treatment with monoclonal antibodies (usually in a cocktail). An understanding of how antibodies bind, whether they compete, and how likely it is that the epitope might mutate to escape neutralisation, is useful in choosing an effective combination. The neutralising non-ACE2 blocking epitope is concealed when the receptor binding domain is packed down, being involved in proteinprotein interactions within the spike, perhaps reducing the likelihood of escape mutations being viable [58] . There is also considerable interest in the potential of nanobodies, camelid antibody fragments about 1/12 th the size of an IgG molecule. These may have direct therapeutic application, and their small size might allow them to be administered intranasally [62] . Work centered at the Rosalind Franklin Institute engineered nM binders through affinity maturation [56] and ongoing work aims to produce more potent molecules. The COVID-19 pandemic exemplifies science as a model for global cooperation. Structural biology infrastructure can strengthen communities [63] and international organisations (such as Instruct-ERIC and EMBL in Europe) play a role, as does EU funded trans-national access (e.g. iNEXT-Discovery). To provide a single exemplar, Instruct was able to respond rapidly to the COVID-19 pandemic (see https://instruct-eric.eu/covid19) and, at the request of UK government funders and Wellcome, Instruct repurposed its ARIA access management system to provide a web platform to offer SARS-CoV-2 reagents, sourced from UK research institutions, to research groups mainly in the UK and Europe. The accelerated research by providing quality-controlled reagents and reducing duplication of effort (https://covid19proteinportal.org/). The major structural biology infrastructures have been largely able to remain functional during lockdowns, facilitated by automation and remote access. Several special, rapid access calls were launched. In Diamond all beamlines and microscopes were available for COVID-19 research, and this remains a priority, 60 applications have been awarded time, and frequently applicaitons have been granted multiple experimental sessions, sometimes spanning multiple techniques. Projects have used a range of instruments, including VMXi, I03, I04, I04-1, I24, B21 and B24, but principally either cryo-EM (with 174 days of microscope time used), or crystallography. Notably ~13,000 XChem data sets have been collected, covering in addition to that described above, eight further fragment campaigns. For the future there is tremendous scope for correlative imaging and cryo-tomography. A glimpse of the prospects comes from Peijun Zhang's group, who have imaged the SARS-CoV-2 infection process at the cellular, sub-cellular and molecular level using a combination of soft X-ray tomography, cryoFIB/SEM, cryo-electron tomography and sub-tomogram averaging using J o u r n a l P r e -p r o o f correlative workflows. These methods are a major focus for Diamond and we aim to accelerate development by co-location [64] . In summary, the rapidity with which relevant structures were determined demonstrates that structural biology is fit for purpose as a central component of the response to emerging/re-emerging viruses. Much will be done to hone the methods, but the larger challenge is to join up all the dots beyond structural biology, avoid market failure and produce effective drugs far more rapidly than has been possible in the past. Some of these challenges are discussed in [6] . We argue that there is an urgent need to establish partnerships to identify and remove bottlenecks and de-risk the process, from surveillance through to virology, biochemistry and structural studies back to chemistry, virology and regulation. This is a moral imperative, and in these difficult times it was good to hear the UK Prime minister recognising the divisions caused by COVID-19 in an address to the United Nations on the 26 th September 'here in the UK … we are determined to do everything in our power to work with our friends across the UN, to heal those divisions and to heal the world'. We expect that science will continue to lead this process by example. Figures Fig. 1 Schematic of the RNA genome of SARS-CoV-2 showing the 3D structural coverage to date. Cleavage sites indicated by orange and blue arrowheads for M pro and PL pro , respectively. The boxes for the ORFs are approximate and the boxes representing the 6 accessory proteins are larger for clarity [8] . The following PDBs were used to generate the representative structures: 7K7P; 6WEN [65] ; 6WRH; 6YB7 [14] ; 6YYT [15] ; 6WXD [66] ; 6W4H [67] ; 6ZSL; 6VWW [68] ; 6VXX [69] ; 7KEG [70] ; 6WZQ [71] ; 6XDC [72] ; 6W37; 7JTL [73] . J o u r n a l P r e -p r o o f the Oxford COVID-19 donation fund, repurposed funds from UKRI and Wellcome, the Chinese Academy of Medical Sciences and the Schmidt Foundation WHO Declares COVID-19 a Pandemic Study Group of the International Committee on Taxonomy of, The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 An interactive web-based dashboard to track COVID-19 in real time The socio-economic implications of the coronavirus pandemic (COVID-19): A review Socio-Economic Impacts of COVID-19 on Household Consumption and Poverty How to help the free market fight coronavirus A Genomic Perspective on the Origin and Emergence of SARS-CoV-2 The Architecture of SARS-CoV-2 Transcriptome Molecular immune pathogenesis and diagnosis of COVID-19 A pneumonia outbreak associated with a new coronavirus of probable bat origin A Novel Coronavirus from Patients with Pneumonia in China A new coronavirus associated with human respiratory disease in China Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease Structure of replicating SARS-CoV-2 polymerase Free fatty acid binding pocket in the locked structure of SARS-CoV-2 spike protein The SARS-CoV-2 Spike harbours a lipid binding pocket which modulates stability of the prefusion trimer Molecules made to measure Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation Where is crystallography going? A poised fragment library enables rapid synthetic expansion yielding the first reported inhibitors of PHIP(2), an atypical bromodomain Pre-clustering data sets using cluster4x improves the signal-to-noise ratio of high-throughput crystallography drug-screening analysis A multi-crystal method for extracting obscured crystallographic states from conventionally uninterpretable electron density The resolution revolution Atomic-resolution protein structure determination by cryo-EM Single-particle cryo-EM at atomic resolution Recent discovery and development of inhibitors targeting coronaviruses An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra alpha-helical domain 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice alpha-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor Production of authentic SARS-CoV M(pro) with enhanced activity: application as a novel tag-cleavage endopeptidase for protein overproduction Structures of two coronavirus main proteases: Implications for substrate binding and antiviral drug design Coronaviruses: an overview of their replication and pathogenesis Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors Upgrade of macromolecular crystallography beamline BL17U1 at SSRF Structure-guided fragment-based drug discovery at the synchrotron: screening binding sites and correlations with hotspot mapping Crowdsourcing drug discovery for pandemics Open Science Discovery of SARS-CoV-2 Main Protease Inhibitors by Combining Crowdsourcing, High-Throughput Experiments, Computational Simulations, and Machine Learning The ReFRAME library as a comprehensive drug repurposing library and its application to the treatment of cryptosporidiosis Discovery of SARS-CoV-2 antiviral drugs through largescale compound repurposing Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report Repurposed antiviral drugs for COVID-19 -interim WHO SOLIDARITY trial results Discovery of an essential nucleotidylating activity associated with a newly delineated conserved domain in the RNA polymerase-containing protein of all nidoviruses Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir Structural Basis for RNA Replication by the SARS-CoV-2 Structural basis for the inhibition of the SARS-CoV-2 RNA-dependent RNA polymerase by favipiravir-RTP Structure of the RNA-dependent RNA polymerase from COVID-19 virus Structural Basis for Helicase-Polymerase Coupling in the SARS-CoV-2 Replication-Transcription Complex Enisamium is a small molecule inhibitor of the influenza A virus and SARS-CoV-2 RNA polymerases Differential occupational risks to healthcare workers from SARS-CoV-2 observed during a prospective observational study Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2 Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike The democratization of cryo-EM SARS-CoV-2 Assembly and Egress Pathway Revealed by Correlative Multi-modal Multi-scale Cryo-imaging Crystal structures of SARS-CoV-2 ADP-ribose phosphatase: from the apo form to ligand complexes Crystal Structure of the SARS-CoV-2 Nonstructural Protein 9 Crystal structure of SARS-CoV-2 nsp10/nsp16 2'-Omethylase and its implication on antiviral drug design Crystal structure of Nsp15 endoribonuclease NendoU from SARS-CoV-2 Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein Envelope Protein in Phospholipid Bilayers Architecture and self-assembly of the SARS-CoV-2 nucleocapsid protein Cryo-EM structure of the SARS-CoV-2 3a ion channel in lipid nanodiscs Structure of SARS-CoV-2 ORF8, a rapidly evolving coronavirus protein implicated in immune evasion Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors D344-D353of Protein structures determined from SARS-CoV-2 and collated in the Protein Data Base Europe Knowledge Base We thank the staff of Diamond Light Source for providing support and encouragement which allowed us to carry out this work during the COVID-19 lockdown in the UK. In particular the Diamond MX (I03, I04, I04-1/XChem, I24, VMXi, XFEL-hub) and eBIC groups for providing essential instruments, support and expertise. There has been huge input Structures determined ☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.☐ The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:Please note that all Biochemical and Biophysical Research Communications authors are required to report the following potential conflicts of interest with each submission. If applicable to your manuscript, please provide the necessary declaration in the box above.(1) All third-party financial support for the work in the submitted manuscript.(2) All financial relationships with any entities that could be viewed as relevant to the general area of the submitted manuscript.(3) All sources of revenue with relevance to the submitted work who made payments to you, or to your institution on your behalf, in the 36 months prior to submission. (4) Any other interactions with the sponsor of outside of the submitted work should also be reported. (5) Any relevant patents or copyrights (planned, pending, or issued). (6) Any other relationships or affiliations that may be perceived by readers to have influenced, or give the appearance of potentially influencing, what you wrote in the submitted work. As a general guideline, it is usually better to disclose a relationship than not.